Tuftsin
Overview
Tuftsin is a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) cleaved from the Fc portion of the heavy chain of immunoglobulin G. It binds to specific receptors on phagocytes, enhancing chemotaxis, phagocytosis, and microbicidal activity.
Mechanism of Action
The therapeutic rationale is to augment innate immune responses in immunocompromised states or chronic infections..
Research Summary & Key Findings
Clinical studies in the 1980s and 1990s evaluated tuftsin and synthetic analogs in cancer, infections, and immune deficiency with modest benefit observed in small cohorts. No large-scale pivotal trials or regulatory approvals have been achieved, and the peptide remains investigational.
Clinical Status
Tuftsin is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
Related Peptides in Immune
Thymalin
InvestigationalA peptide bioregulator originally extracted from bovine thymus gland, consisting of a mixture of polypeptides that modul...
View detailsLL-37
Research PhaseThe only human cathelicidin antimicrobial peptide, a 37-amino acid cationic peptide cleaved from the precursor protein h...
View detailsVIP (Vasoactive Intestinal Peptide)
InvestigationalA 28-amino acid neuropeptide widely distributed in the central and peripheral nervous systems and immune cells. VIP acts...
View detailsThymosin Alpha 1 (Zadaxin)
InvestigationalA 28-amino acid peptide originally isolated from thymic tissue (thymosin fraction 5) that serves as a potent immunomodul...
View detailsFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Tuftsin.
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.